Polyrizon Ltd (PLRZ) 12.72 USD (-3.85%) | Healthcare NASDAQ

Polyrizon Ltd develops biotechnological treatment technologies aimed at preventing viral and allergenic entry through biological barriers.

biotechnology

Comment

Performance & Momentum

6 Months 25.82 %

1 Year 179.68 %

3 Years 99.45 %

5 Years 99.28 %

Momentum

Unlock this indicator

Recent News

Polyrizon Ltd

Polyrizon Gets Nasdaq Delisting Notice

1 year ago

On May 23, 2025, Polyrizon Ltd announced that it had received a Nasdaq delisting notice, triggering a sharp 25% drop in its share price. The decline reflects strong market concern over the company's ability to maintain its listing, weighing on investor confidence.

source: globenewswire.com • delisting

Strategic Analysis

Polyrizon Ltd positions itself in the biotechnology sector by developing innovative solutions aimed at strengthening biological barriers against viral infections and allergens. Its model is based on targeted treatment technologies, offering a differentiated approach to disease prevention in the healthcare sector.

Strengths

Innovative approach focused on prevention through the strengthening of biological barriers
Focus on high-potential medical biotechnology solutions
Presence in Israel, a recognized hub for biotech research

Weaknesses

History of significantly degraded financial performance over the medium and long term
Lack of positive momentum and recent relevance

Momentum

The momentum is neutral to non-existent, signaling a lack of interest or recent positive catalysts. The high volatility and decline in past performance suggest a high-risk profile that requires vigilance and increased monitoring of clinical or strategic developments to consider a recovery.

Analysis performed 3 months ago